Page last updated: 2024-09-03

hrp 102 and Weight Gain

hrp 102 has been researched along with Weight Gain in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
el-Hussinie, M; el-Nahal, N; Hassan, EO1
Albrecht, G; Arboleda, C; Bailon, R; Bassol, S; Bucheli, R; Carneiro de Oliveira, H; Carranza, S; CastaƱeda, A; Celis, C; Chada, E; Cravioto, MC; de Andrade, ME; de Mello, NR; de Melo, K; Durand, M; Fugarolas, J; Gaona, R; Garza-Flores, J; Gomez, P; Gurucharri, C; Hidalgo, I; Lopez, C; Mendez, J; Novelli, J; Olavide, R; Parada, LM; Parejarios, J; Reyes-Marquez, R; Santoyo, S; Succar, J; Trujillo, L; Vazquez, L; Yassle, ME1

Trials

2 trial(s) available for hrp 102 and Weight Gain

ArticleYear
Once-a-month injectable contraceptives, Cyclofem and Mesigyna, in Egypt. Efficacy, causes of discontinuation, and side effects.
    Contraception, 1999, Volume: 60, Issue:2

    Topics: Adult; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Drug Administration Schedule; Drug Combinations; Egypt; Estradiol; Female; Humans; Injections, Intravenous; Medroxyprogesterone Acetate; Norethindrone; Patient Compliance; Weight Gain

1999
Mesigyna once-a-month combined injectable contraceptive: experience in Latin America.
    Contraception, 2000, Volume: 61, Issue:5

    Topics: Adolescent; Adult; Amenorrhea; Blood Pressure; Contraceptive Agents, Female; Drug Combinations; Estradiol; Female; Humans; Injections; Latin America; Norethindrone; Pregnancy; Uterine Hemorrhage; Weight Gain

2000